
In this video from the April 2025 WCPD symposium, Dr Amy Paller discusses the pathophysiology of skin barrier dysfunction in AD and how regulating IL-4 and IL-13 signaling may lead to restoration of the skin barrier. Dr Paller goes on to explore how reducing certain biomarkers, such as CCL17 (TARC), may reduce inflammation that contributes to AD severity in pediatric patients.
Join Dr. Nirmala Gonsalves as she reviews symptoms of EoE and tools to assess symptoms in patients with EoE.
Join Dr. Nirmala Gonsalves as she reviews some of the tools to assess quality-of-life outcomes in patients with EoE.
Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.
Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.
Hear Dr. Evan Dellon outline the benefits of maintenance therapy in EoE and the importance of an individualized treatment approach for each patient.

Dr Kwatra poses the question: How do we assess disease modification in PN, and can treating early stop tissue damage and worsening of systemic diseases associated with PN?
This chapter highlights how a food bolus impaction may be the initial manifestation of a patient with EoE masked by adaptive eating behavior.
This chapter highlights different endoscopic features of EoE that one may find during an upper endoscopy.
This chapter highlights other histologic features beyond eosinophil count that may be present in patients with EoE.
This chapter focuses on the importance of shared decision-making and regular, long-term monitoring of histology and endoscopy, not just symptoms.
Professor Dédée Murrell explains the challenges in managing patients with bullous pemphigoid at EADV 2025